Hartaj Singh, analyst at Oppenheimer, initiates coverage on Oncternal Therapeutics Inc. (ONCT) with a Buy rating and has set a price target of $16.00. TipRanks.com has Singh rated as a 4.5-star analyst with a 15% return on investment and a 46% success rate.
TipRanks.com reports that ONCT currently has 4 analysts offering 12 month price targets and the consensus is a Strong Buy rating with an average price target is $15.50. The target pricing ranges from a high forecast of $21.00 down to a low forecast of $9.00.
ONCT’s last price was $6.48 which would put the average price target at 139.20% upside.
Other analysts covering ONCT include:
- Ram Selvaraju (H.C. Wainwright) Buy
- Carl Byrnes (Northland Securities) Buy
- Kumaraguru Raja (Brookline Capital Management) Buy
TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>